Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Feb 23;10(2):e0118210.
doi: 10.1371/journal.pone.0118210. eCollection 2015.

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer

Affiliations

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer

Monika Joshi et al. PLoS One. .

Abstract

V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) mutated lung cancer is relatively aggressive and is resistant to currently available therapies. In a recent phase II study for patients with BRAF-V600E non-small cell lung cancer (NSCLC), BRAF V600E inhibitor demonstrated evidence of activity, but 30% of this selected group progressed while on treatment, suggesting a need for developing alternative strategies. We tested two different options to enhance the efficacy of vemurafenib (BRAF V600E inhibitor) in BRAF mutated NSCLC. The first option was the addition of erlotinib to vemurafenib to see whether the combination provided synergy. The second was to induce MEK inhibition (downstream of RAF) with trametinib (MEK inhibitor). We found that the combination of vemurafenib and erlotinib was not synergistic to the inhibition of p-ERK signaling in BRAF-V600E cells. Vemurafenib caused significant apoptosis, G1 arrest and upregulation of BIM in BRAF-V600 cells. Trametinib was effective as a single agent in BRAF mutated cells, either V600E or non-V600E. Finally, the combination of vemurafenib and trametinib caused a small but significant increase in apoptosis as well as a significant upregulation of BIM when compared to either single agent. Thus, hinting at the possibility of utilizing a combinational approach for the management of this group of patients. Importantly, trametinib alone caused upregulation of p-AKT in BRAF non-V600 mutated cells, while this effect was nullified with the combination. This finding suggests that, the combination of a MEK inhibitor with a BRAF inhibitor will be more efficacious in the clinical setting for patients with BRAF mutated NSCLC.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Investigating the effects of the vemurafenib and erlotinib combination in BRAF and KRAS mutant NSCLC cells.
A: Western blot of phosphorylated AKT and ERK signaling in native untreated cell lines ([+] mutated; [–] wildtype). All lanes are from the same gel and break was created to include only relevant cell lines B: A549, H460, H1755 and HCC364 cell lines treated with D (DMSO) or indicated drugs, E (erlotinib), V (vemurafenib), and EV (erlotinib-vemurafenib) were analyzed after 72h by a MTS assay. The IC50 for Vemurafenib in HCC364 was 0.8 μM. C: Western blot of different NSCLC cell lines, showing changes in p-ERK, p-AKT and PARP with vehicle D (DMSO), E (erlotinib) 1.6 μM, V (vemurafenib) 1.6 μM, EV (erlotinib+vemurafenib) 1.6/1.6, μM after 24h treatment. D: Apoptosis by flow cytometry 48h post treatment with D (DMSO), E (erlotinib) 1.6 μM, V (vemurafenib) 1.6 μM, EV (erlotinib/vemurafenib 1.6/1.6 μM). Western blot, post 48h, supporting PARP cleavage with V and EV in HCC364 but not H1755 cells.
Fig 2
Fig 2. Effects of single-agent vemurafenib on BRAF mutated NSCLC cells.
A: Long-term growth assay, 7 days post treatment with vehicle-D (DMSO), vemurafenib 50 nM, 500 nM, 5000 nM in both HCC364 and H1755 cells. HCC364 cells were more sensitive to vemurafenib. * p< 0.05; *** p<0.001 when compared to DMSO. B: Cell cycle analyses by flow cytometry 24h post treatment with DMSO, V (vemurafenib) in HCC364 and H1755 cells. Cell cycle phases shown are G1, S and G2 phase. V induces cell cycle arrest in HCC364 cells, as evidenced by an increase in G1 and a significant decrease in S phase. C: Western blot at 48 hours post treatment supporting the evidence for G1 arrest, showing increase in p27 and decrease in CDk2 with V (vemurafenib) when compared to D (DMSO). No effect was seen in H1755 cells. All lanes for HCC364 and all lanes for H1755 are from the same gel. The break has been created to remove erlotinib treated lanes.
Fig 3
Fig 3. Growth and cell cycle effects of trametinib and vemurafenib combination on BRAF mutated NSCLC cell lines.
A, B: Long-term growth assay, 7 days post treatment with vehicle-DMSO (D), V (vemurafenib) 1 μM, T (trametinib) 1 μM and TV (trametinib + vemurafenib, 1 μM each) in HCC364 (A), and H1755 cells (B). C: Cell cycle analyses by flow cytometry in HCC364 and H1755 cells after 24 hours treatment with D, V 0.5 μM, T 0.5 μM, TV 0.5/0.5 μM. D: Western blot after 24h of H1755 and HCC364 treated like in C. (***p<0.001 when compared to DMSO).
Fig 4
Fig 4. Anti-apoptotic effects of trametinib and vemurafenib in BRAF mutated NSCLC cell lines.
A: Apoptosis by flow cytometry, 48h post treatment with vehicle-D (DMSO), V (vemurafenib 1 μM), T (trametinib 1 μM), TV (trametinib + vemurafenib 1/1 μM) in HCC364 and H1755 cells. (*p<0.05;** p <0.01; *** p<0.001). B: Western blot of cleaved PARP in HCC364 and H1755, 48h post treatment with D (DMSO) and varying doses of vemurafenib (0.25, 0.5, 1μM) and trametinib (0.25, 0.5, 1μM) C: Western blot showing changes in ERK, AKT, BIM, PARP cleavage, 48h post treatment with vehicle D (DMSO), V (vemurafenib 1 μM), T (trametinib 1 μM), TV (trametinib + vemurafenib 1/1μM) in HCC364 and H1755 cells. Four lanes were treated in duplicates for each cell lines and only the left 4 lanes of each cell lines have been shown in the figure.

Similar articles

Cited by

References

    1. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361: 958–967. 10.1056/NEJMoa0904554 - DOI - PubMed
    1. Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043. - PubMed
    1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132. - PubMed
    1. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, et al. (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742. 10.1016/S1470-2045(11)70184-X - DOI - PubMed

MeSH terms

Grants and funding

The authors have no support or funding to report.